Table 4 Univariate Cox Proportional Hazards models of pre- and post-transplantation factors predicting overall survival.
Hazard ratio (95% CI for HR) | p-value | |
|---|---|---|
Pre-transplantation factors | ||
JAK2 mutation present | 0.76 (0.34–1.70) | 0.51 |
Age at transplant (>55 years vs. <55 years) | 1.18 (0.51–2.72) | 0.69 |
DIPSS stratification (high risk vs. intermediate-2) | 2.21 (0.52–9.47) | 0.28 |
JAK inhibitor therapy prior to SCT | 0.93 (0.38–2.23) | 0.86 |
Pre-HCT RBC transfusion dependence | 4.36 (1.31–14.60) | 0.02 |
Pre-HCT platelet transfusion dependence | 0.76 (0.23–2.52) | 0.65 |
High risk cytogenetics | 3.04 (1.26–7.34) | 0.01 |
Conditioning regimen (reduced intensity vs. myeloablative) | 0.59 (0.24–1.49) | 0.27 |
Graft vs. host disease prophylaxis (Calcineurin inhibitor + methotrexate vs. Calcineurin inhibitor + mycophenolate) | 0.79 (0.32–2.02) | 0.64 |
Donor source (matched related vs. other) | 0.66 (0.30–1.45) | 0.30 |
Anti-thymocyte globulin administered | 0.45 (0.19–1.07) | 0.07 |
Post-transplantation (day +100) factors | ||
RBC transfusion dependence | 8.06 (3.45–18.85) | <0.001 |
Platelet transfusion dependence | 7.24 (3.29–15.95) | <0.001 |
100% Donor chimerism in CD3 + cells | 1.01 (0.33–3.08) | 0.99 |
100% Donor chimerism in CD33 + cells | 0.28 (0.09–0.91) | 0.03 |
Grade ≥2 bone marrow fibrosis (vs. Grade ≤1) | 2.72 (1.00–7.41) | 0.05 |
No improvement in bone marrow fibrosis | 1.96 (0.84–4.55) | 0.12 |
Acute GVHD (Grades 2–4 vs. Grade 0–1) | 0.96 (0.29–3.20) | 0.95 |
Normal spleen size | 0.55 (0.24–1.29) | 0.17 |
Unfavorable molecular status | 4.1 (1.64–10.24) | 0.003 |
Poor graft function day +100 | 2.06 (0.92–4.64) | 0.08 |
